Cas:135-09-1 hydroflumethiazide manufacturer & supplier

We serve Chemical Name:hydroflumethiazide CAS:135-09-1 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

hydroflumethiazide

Chemical Name:hydroflumethiazide
CAS.NO:135-09-1
Synonyms:EINECS 205-173-8;Robezon;Spandiuril;Saluron;MFCD00057316;hydroflumethyazide;Glomerulin;hydroflumenthiazide;Diurometon;hydroflumethiazide;Flutizide;Hidroflumetiazid;Diuredemina;Hidroalogen
Molecular Formula:C8H8F3N3O4S2
Molecular Weight:331.29200
HS Code:2935009090

Physical and Chemical Properties:
Melting point:272-273ºC
Boiling point:531.6ºC at 760 mmHg
Density:1.678g/cm3
Index of Refraction:1.55
PSA:135.12000
Exact Mass:330.99100
LogP:3.34280

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like EINECS 205-173-8 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,Hidroalogen physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,MFCD00057316 Use and application,Spandiuril technical grade,usp/ep/jp grade.


Related News: India and China are two of the leading players in that game, and US legislators for months have pushed for an aggressive “onshoring” of drug production to counteract the nation’s reliance on foreign producers. Israel, a key ally to the US, could be a logical partner in that effort, but the Trump administration also took out big bets on US firms to set up shop stateside. 3-[(E)-(4-chlorophenyl)methylidene]-1,3-dihydro-2H-indol-2-one manufacturers Grégoire brings more than 20 years of technological innovation, strategy and digital entrepreneurship experience to the team. He started his career as the founder and CEO of Andrexen, an innovative Unified Communication Cloud Platform. (4S,5S,6S)-4-hydroxymethyl-5-iodo-6-methyl-1,3-oxazin-2-one suppliers J.P. Morgan and William Blair analysts still backed iRhythm for the long-term despite its recent challenges. William Blair analysts wrote that the company is still a leader of a cardiac monitoring market that is under 20% penetrated and valued at approximately $2 billion. 1-Methyl-3-phenyl-4-oximino-piperidin vendor & factory.